Clinical TrialApr 22, 2026, 07:03 AM
Nurix presents positive preclinical oncology data at AACR 2026
AI Summary
Nurix Therapeutics announced new positive preclinical data from its oncology pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026. The presentations highlighted continued progress across programs targeting pan-mutant BRAF, CBL-B, and Aurora Kinase A (AURKA), reinforcing the potential of degraders to overcome limitations of traditional inhibitors. Specifically, the pan-mutant BRAF degrader NRX-0305 demonstrated potent antitumor activity and significantly extended survival by 142% in a resistant melanoma brain metastasis model, suggesting a promising new therapeutic modality.
Key Highlights
- NRX-0305 extended survival by 142% in a BRAF inhibitor-resistant melanoma brain metastasis model.
- Demonstrated broad activity across 14 PDX models of Class 1, 2, and 3 BRAF-mutant cancers.
- Showed potent antitumor activity in intracranial glioma and melanoma models.
- Highlighted advances in pan-mutant BRAF, CBL-B, and AURKA oncology programs.
- CSO to present on targeted protein degradation at AACR Advances session.
Price Impact
More from NRIX